Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term outcomes. Waiting too long to start treatment not only raises the chances of serious complications, but also leads to more doctor visits and higher costs. Managed care professionals find themselves in the middle of this friction, and prompt access to treatment relies on understanding of the latest data for proper positioning of therapies on formulary. As new treatments emerge, it is essential to determine which treatments are preferred based on safety and efficacy data that prove clinical significance and drive decisions for patient coverage.
In this CME Outfitters recorded symposium led by a multi-disciplinary panel of UC experts, clinicians will learn about the changes happening in the UC treatment landscape, which treatments may offer patients with UC a higher quality of life, and which UC treatments have significant long-term benefit, thus optimizing access to the best treatments available to patients in different stages of disease.
At the conclusion of this activity, learners will be able to better:
This activity is supported by an independent educational grant from Lilly.
Managed care professionals including physicians, physician associates (PAs), pharmacists, payers, pharmacy benefit managers, and clinicians within IDSs
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-066-H01-P).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 10/18/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Naik reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Benson reports no financial relationships to disclose.
Dr. Spiegel reports the following financial relationships:
Advisory Board: Ardelyx and Exact Sciences Corporation
Grants: AbbVie Inc.; Amgen Inc.; Ardelyx; Ironwood; and Salix Pharmaceuticals
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Joshua Caballero, PharmD, BCPP, FCCP (Peer reviewer)
Thomas Mitchell, MSW (Planning Committee)
Chelsey Goins, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
MMV-145-101824-11
